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Edited by Varda RotterAbstract Okadaic acid (OA) is a protein phosphatase (PP)
inhibitor and induces hyperphosphorylation of p53. We investi-
gated whether the inhibition of PP1 by OA promotes the
phosphorylation of the serine 15 of p53. In vitro dephosphoryl-
ation assay showed that PP1 dephosphorylated ultraviolet C
(UVC)-induced phospho-ser15 of p53, and that OA treatment
inhibited it. One of the PP1 regulators, growth arrest and DNA
damage 34 (GADD34), disturbed PP1 binding with p53,
interfered with the dephosphorylation of p53 and increased the
amount of phospho-p53 after UVC-treatment. This report
provides the ﬁrst evidence that PP1, but not PP2A, dephosph-
orylates phospho-serine 15 of p53.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tumor suppressor p53 is tightly regulated by phosphoryla-
tion. The phosphorylated p53 induces cell-growth arrest
and/or apoptosis through p53 response gene transcription.
DNA-damaging stress, such as c-irradiation and ultraviolet
(UV) irradiation, activates ATM/ATR kinases, which in turn
phosphorylate the serine 15 residue of p53 protein [1]. The
phosphorylated serine 15 promotes the interaction with p300
[2], and p300 acetylated p53 and histones, which enhances
promoter activity of p53 response gene. It remains unclear
whether phospho-serine 15 stabilizes p53 protein. On the other
hand, the serine 20 residue of p53 is phosphorylated by CHK
proteins [3–5], and is the important site of interaction to
MDM2 protein. Phosphorylation of serine 20 dissociates from
MDM2, which promotes p53 stability [6].
It has been shown that multiple protein phosphatases (PPs)
can dephosphorylate p53 in vitro. These phosphatases include* Corresponding author. Fax: +81-562-44-6591.
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Abbreviations: OA, okadaic acid; GADD, growth arrest and DNA
damage; UVC, ultraviolet C; MMS, methyl methanesulfonate
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doi:10.1016/j.febslet.2004.04.066PP1, PP2A, PP5, Wip1 and Cdc14 [7–10]. Under normal
condition, PP1/PP2A dephosphorylates the C-terminal of p53
protein; this site is phosphorylated by protein kinase C, which
inﬂuences the DNA binding ability of p53 and transcriptional
activity [11]. Meanwhile, the phosphorylation at the N-termi-
nal of p53 is important for transcription and stabilization
[12,13], but dephosphorylation of that site has not been well
studied. Okadaic acid (OA), the inhibitor of PP1 and PP2A
[14], accumulates hyperphosphorylated p53 [15,16] and the
PP2A inhibitor, SV40 small t antigen, promotes the DNA
binding ability of p53 and the transcriptional activity [17]. One
of the PP1 regulators, growth arrest and DNA damage 34
(GADD34) (PPP1R15A, myd116), increases the amount of
total and phosphorylated p53, and promotes p21 (waf1)
mRNA expression [18]. These studies show that PPs regulate
p53 through these phosphatase activities. Under stressed
condition, however, the relations between PPs and p53 have
been unclear.
In the present study, we show the relation between p53 and
PP1 under DNA damaging conditions. We demonstrate that
OA increases the amount of phosphorylation at the serine 15,
which is related to the inactivation of PP1. Furthermore, by
using GADD34 deﬁcient MEFs, we show that the regulation
of PP1 inﬂuenced p53 phosphorylation in vivo. These results
suggest that PP1 is the key regulator of p53 and is the major
phosphatase of phospho-serine 15 of p53.2. Materials and methods
2.1. Cell lines and transfection
Human WI38 cells and HEK293 cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (GIBCO) supplemented with 10% fetal bo-
vine serum (GIBCO). Human p53 null cell lines SOAS-2 were main-
tained in modiﬁed McCoy’s 5A medium (GIBCO) with 15% fetal
bovine serum (FBS). All cells were grown at 37 C in a humidiﬁed
atmosphere of 5% CO2. Transfections were performed with the eﬀec-
tene reagent (Qiagen). Methyl methanesulfonate (MMS) was pur-
chased from Sigma–Aldrich.
2.2. Preparation of mouse embryonic ﬁbroblasts
Mouse embryonic ﬁbroblasts (MEFs) from GADD34-deﬁcient mice
and wild-type mice were prepared from 14.5-day-old embryo [19]. All
cultures were maintained in Dulbecco’s modiﬁed essential medium
(Sigma) with 10% FBS. Cells were plated 2 106 cells/10-cm plates for
subculture.blished by Elsevier B.V. All rights reserved.
Fig. 1. OA increases p53 phosphorylation by UVC treatment. WI38
cells were treated by UVC (50 J/m2) for 4 h with increasing concen-
trations of OA. Phosphorylated p53 (top panel) and total p53 (middle
panel) were determined. As a control, b-actin levels were determined
(bottom panel). These are the representative data of more than two
experiments.
172 M. Haneda et al. / FEBS Letters 567 (2004) 171–1742.3. Plasmids
Human p53 expression vector was provided by Bai and Merchant
[20]. PP1 cDNA was purchased from Invitrogen and cloned into the
BamHI/XbaI site of pcDNA3.1HisA vector with Xpress tag. Mouse
GADD34 myc-tagged expression vector was described previously [18].
SV40 small t antigen cDNA was obtained by polymerase chain reac-
tion (PCR) ampliﬁcation using the cDNA of COS-1 cells as a template
and employing 50- and 30-oligonucleotide primers. The oligonucleo-
tides used in this experiment were as follows: small t antigen 50-probe:
50- CGGGATCCATGGATAAAGTTTTAAACAGAG -30; small t
antigen 30-probe: 50-CCGCTCGAGTTAGAGCTTTAAATCTCTG-
TA -30. The fragments were subcloned into the BamHI/XbaI site of
pcDNA3.1HisA vectors. Sequences were conﬁrmed by dideoxy se-
quencing. When cDNA expression vectors were transfected, protein
synthesis was inhibited by the phosphorylation of eukaryotic transla-
tion initiation factor 2 alpha (eIF2aÞ. We employed pAdVantage
vector (Promega) to preclude the termination of protein synthesis.
2.4. DNA-damaging and phosphatase-inhibitor treatments
WI38 cells and MEFs were grown to 50–80% conﬂuence in 6-cm
dishes in DMEM containing 10% FBS. DNA damage was achieved by
exposing the cells to ultraviolet C (UVC) (50 J/m2) or MMS (80 lg/
ml). Cells were harvested at indicated time points. In some experi-
ments, they were treated with increasing concentrations of OA (from 1
to 100 nM) 6 h before DNA-damage treatment. Four hours after
irradiation, cells were treated with 10 lg/ml of cyclohexamide to
arrest new p53 protein synthesis and cells were then harvested at the
indicated time points. OA and cyclohexamide were purchased from
Sigma.
2.5. Immunoblotting
Proteins were analyzed by SDS–PAGE and detected by a chemilu-
minescent ECL kit (Amersham) with one of the following antibodies:
anti-p53 antibody, anti-phospho-ser15 p53 antibody (Cell signaling),
anti-GFP antibody (BD Biosciences), anti-GADD34 antibody (Santa
Cruz), anti-eIF2a antibody (Santa Cruz), anti-phospho-ser 51 eIF2a
antibody (BIOSOURCE international), anti-p21 (waf1) antibody
(Santa Cruz), and anti-b-actin antibody (Amersham).
2.6. In vitro dephosphorylation assay
WI38 cells wereUVC-treated (100 J/m2) and 1 h later the cells were
lysed in low-stringency buﬀer (50 mM Tris–HCl, pH 7.5; 120 mM
NaCl; 0.5 mM EDTA; and 0.5% NP-40) in the presence of PMSF and
protease inhibitors. After pre-cleaning with protein G beads (Amer-
sham), the extracts were immunoprecipitated with anti-p53 antibody in
the presence of protein G beads for 4 h at 4 C. The beads were then
washed three times with low-stringency buﬀer, and twice with PP1
reaction buﬀer containing 1 mM MnCl2 and 5 mM caﬀeine. One unit
of PP1 (New England Biolabs, Inc.) was added to the immune com-
plexes for 1 h at 30 C. For inhibition studies, the immune complexes
and PP1 were incubated with 1 lM of OA in PP1 reaction buﬀer for
1 h at 30 C. For positive control studies, Calf intestine alkaliphos-
phatase (CIAP) (Takara) was added to the immune complexes in CIAP
buﬀer for 1 h at 37 C. Dephosphorylation was analyzed by SDS–
PAGE and was detected by immunoblotting with anti phospho-serine
15 of p53 antibody.3. Results
3.1. Okadaic acid increases UVC-induced phosphorylation at
serine 15 residue of p53
OA is a inhibitor of PP1 and PP2A. To evaluate the role of
PP1/PP2A in regulating p53 phosphorylation after DNA-
damaging stress, WI38 cells were exposed to UVC (50 J/m2)
with increasing concentrations of OA. As shown in Fig. 1, the
high concentrations of OA (100 nM) induced an increase in
phosphorylated serine 15 of p53. On the other hand, the low
concentrations of OA (1 nM) slightly reduced the phosphor-
ylation of p53 after UVC treatment. The same treatment did
not aﬀect the amount of b-actin. These results demonstratethat PP1 and/or PP2A regulated the phosphorylation at the
serine 15 of p53 through phosphatase activity.
3.2. Protein phosphatase 1, but not protein phosphatase 2A, is
the key regulator of phospho-serine 15 of p53
High concentrations of OA (100 nM) promoted the phos-
phorylation of p53, but it was unclear whether PP1 or PP2A
was more important for the regulation of phospho-serine 15 of
p53. To rule out the possibility that PP2A dephosphorylates
p53, the PP2A inhibitor, SV40 small t antigen, was co-trans-
fected to the culture cells to block p53 dephosphorylation.
After UVC treatment, small t antigen did not aﬀect the
amount of p53, but induced a decrease in phospho-serine 15 of
p53 (Fig. 2). To conﬁrm the possibility that PP1 dephosph-
orylates p53, the PP1 regulator protein, GADD34, was
co-transfected to the cultured cells to block p53 dephospho-
rylation. After UVC treatment, mouse GADD34 increased the
amount of p53 and induced phosphorylation at the serine 15 of
p53 (Fig. 2). These results suggested that GADD34 interfered
in the dephosphorylation of p53, causing an increase in
phospho-serine 15.
3.3. Protein phosphatase 1 dephosphorylates the serine 15
residue of p53 in vitro
Because we found that PP1 bound p53 in vivo, we next in-
vestigated whether PP1 could actually dephosphorylate
phospho-ser15 of p53. We employed in vitro dephosphoryla-
tion assay. As shown in Fig. 3, PP1 dephosphorylated
UVC-induced phospho-ser15 of p53. 1 lM of OA treatment
inhibited the phosphatase activity of PP1. CIAP also dep-
hosphated p53.
3.4. The PP1 regulator GADD34 enhances DNA damage-
induced p53 phosphorylation
To determine the relation between p53 phosphorylation and
GADD34, we analyzed the p53 protein expression and p53
phosphorylation using GADD34 deﬁcient MEFs. In wild-type
MEFs, GADD34 was induced 8 h after MMS treatment
(Fig. 4). And the protein levels of p53 and phospho-serine 18
of mouse p53 (corresponding to serine 15 of human p53) were
highly expressed in a time-dependent manner at 8 h after
MMS treatment. On the other hand, in GADD34-deﬁcient
MEFs, the levels of both p53 and phospho-serine 18 of p53
Fig. 2. Mouse GADD34 promotes phospho-ser 15 of p53 and inter-
feres with the interaction between PP1 and p53. GADD34 promotes
phosphorylation of p53 at serine 15, but SV40 small t antigen decreases
phospho-serine 15. SOAS-2 cells were transfected with 0.1 lg of hu-
man p53 wild-type, 0.1 lg of GFP and 0.2 lg of Advantage vector (all
lanes), and co-transfected with one or more of the following vectors:
0.2 lg of mock vector (lane 1), 0.1 lg of mock vector and 0.1 lg of
small t antigen expression vector (lane 2), 0.2 lg of small t antigen
expression vector (lane 3), 0.1 lg of mock vector and 0.1 lg of mouse
GADD34 expression vector (lane 4), and 0.2 lg of GADD34 expres-
sion vector (lane 5). Phosph-ser 15 of p53 (top panel) and total p53
(middle panel) were determined. GFP was determined as the trans-
fection internal control (bottom panel). These are the representative
data of more than two experiments.
Fig. 4. Determination of p53 and phospho-p53 protein levels in wild-
type and GADD34 deﬁcient MEFs after MMS treatment. Cells were
treated with 80 lg/ml MMS and cell lysates were prepared at the in-
dicated time points. 50-lg lysate was run on 10% SDS–PAGE. To
investigate the status of protein synthesis, we examined total eIF2a and
phosphorylated eIF2a. Total p53, phosphorylated p53 and p21 (waf1)
were determined by immunoblotting. As a control, b-actin levels were
determined. These are the representative data of more than two
experiments.
Fig. 3. PP1 dephosphorylates phospho-ser15 of p53 in vitro. WI38 cells
were UVC-treated (100 J/m2) and p53 protein was immunoprecipitated
with anti-p53 antibody. As a control, the immune complexes were
incubated without PP1 (lane1). One unit of PP1 was added to the
complexes (lane 2). For inhibition studies, the complexes and PP1 were
incubated with 1 lM of OA (lane 3). As a positive control, CIAP was
added to the complexes (lane 4). The products were probed with anti
phospho-serine 15 of p53 antibody (upper panel). Same membrane was
re-probed with anti p53 antibody (lower panel). These are the repre-
sentative data of more than two experiments.
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induction of phosphorylated p53 per total p53 by MMS treat-
ment was lower than that of wild-type MEFs. In GADD34-
deﬁcient MEFs, the level of p21 (waf1, cip1) expression waslower than that in wild-type MEFs. MMS treatment, unlike
endoplasmic reticulum (ER) stress, did not induce the phos-
phorylation of eIF2a (Fig. 4). The same treatment did not
aﬀect the expression of b-actin, indicating that GADD34
protein did not have an overall positive eﬀect on protein
expression after MMS treatment.4. Discussion
PP1 is the cellular protein serine/threonine phosphatase and
the regulator of protein function through dephosphorylation.
Here, we showed that OA treatment enhanced the phosphor-
ylation of p53 at serine 15 after UVC treatment (Fig. 1). OA is
the inhibitor of PP1 and PP2A, and this agent inhibits PP2A
(50% inhibitory dose IC50, 1–10 nM) more potently than PP1
(IC50, 100 nM to 1 lM) [21]. Since 100 nM OA promoted the
phosphorylation of p53, PP1 was thought to be more impor-
tant in phospho-serine 15 of p53. To rule out the possibility
that PP2A dephosphorylates p53, the PP2A inhibitor, SV40
small t antigen, was co-transfected with p53 expression vector
to block p53 dephosphorylation. After UVC treatment, small t
antigen did not aﬀect the amount of p53, but induced a de-
crease in phospho-serine 15 of p53 (Fig. 2). The corresponding
mechanisms remain unknown, but it is suggested that PP2A
may act as a negative regulator of PP1 or activate the serine 15
kinase.
The PP1 regulator, GADD34 (PPP1R15A, myd116), is in-
duced by ER stress [19,22,23], and GADD34 relocates PP1 to
ER for dephosphorylation of eIF2a. We employed GADD34
to conﬁrm the possibility that PP1 dephosphorylates p53.
After UVC treatment, co-transfected mouse GADD34 ex-
pression increased the amounts of total and phospho-ser 15 of
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the relation between GADD34 and p53 phosphorylation
(Fig. 4). In a previous study, we reported that PP1 regulator
GADD34 induced phospho-serine 15 of p53 and promoted p21
(waf1) mRNA expression through p53 DNA binding sites [18].
The phosphorylation at the N-terminal site of p53 is im-
portant for transcription and stabilization [12,13], but the de-
phosphorylation of N-terminal site has not been well studied.
Here, we revealed for the ﬁrst time a relationship between N-
terminal phospho-serine 15 residue of p53 and PP1, and that
phospho-serine 15 temporarily promotes the stability of p53
protein. By in vitro dephosphorylation assay (Fig. 3), we
showed that PP1 actually dephosphorylated phospho-serine 15
of p53. However, it is still unclear whether other phosphory-
lated sites of p53 are dephosphorylated by PP1.
In conclusion, we propose that in response to UVC treat-
ment, p53 is phosphorylated by the serine 15 kinases and
continuously dephosphorylated by PP1 but not by PP2A. This
dephosphorylation requires the phosphatase ability of PP1.
The PP1 regulator GADD34 interferes with the dephospho-
rylation of p53 and increases the phosphorylation at serine 15
of p53. These results support the speculation that GADD34
regulates p53 by modulating its phosphorylation levels.
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